08/27/2024 6:49 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/21/2024 5:03 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/20/2024 3:16 PM | Halozyme Therapeutics (Subject) LaBarre Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2024 3:59 PM | Halozyme Therapeutics (Issuer) Torley Helen (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/15/2024 3:31 PM | Halozyme Therapeutics (Subject) Torley Helen (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/13/2024 3:19 PM | Halozyme Therapeutics (Subject) Torley Helen (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/07/2024 3:41 PM | Halozyme Therapeutics (Subject) Posard Matthew L. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
|
07/24/2024 4:48 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/24/2024 3:05 PM | Halozyme Therapeutics (Subject) LaBarre Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/23/2024 3:11 PM | Halozyme Therapeutics (Subject) LaBarre Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/22/2024 3:13 PM | Halozyme Therapeutics (Subject) LaBrosse Nicole (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/28/2024 3:51 PM | Halozyme Therapeutics (Subject) LaBrosse Nicole (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/27/2024 3:29 PM | Halozyme Therapeutics (Subject) LaBrosse Nicole (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/26/2024 3:16 PM | Halozyme Therapeutics (Subject) LaBrosse Nicole (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/20/2024 3:17 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/18/2024 3:22 PM | Halozyme Therapeutics (Subject) LaBarre Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/14/2024 3:17 PM | Halozyme Therapeutics (Issuer) Snyder Mark Howard (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/11/2024 3:40 PM | Halozyme Therapeutics (Subject) Posard Matthew L. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/22/2024 4:24 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/07/2024 3:05 PM | Halozyme Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/29/2024 4:54 PM | Duncan Barbara Gayle (Reporting) Halozyme Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/29/2024 4:56 PM | Halozyme Therapeutics (Issuer) Henderson Jeffrey William (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/29/2024 5:01 PM | Halozyme Therapeutics (Issuer) Krishnan Mahesh (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/29/2024 5:05 PM | Halozyme Therapeutics (Issuer) MATSUI CONNIE (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/29/2024 5:08 PM | Halozyme Therapeutics (Issuer) Miyashita Akiko Moni (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/29/2024 5:11 PM | Halozyme Therapeutics (Issuer) Posard Matthew L. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/29/2024 4:51 PM | Connaughton Bernadette (Reporting) Halozyme Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/26/2024 3:22 PM | Halozyme Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/17/2024 6:22 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/26/2024 6:38 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/15/2024 3:46 PM | Halozyme Therapeutics (Filer)
| Form ARS | |
03/15/2024 3:18 PM | Halozyme Therapeutics (Filer)
| Form DEFA14A | |
03/13/2024 4:22 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/13/2024 3:14 PM | Halozyme Therapeutics (Subject) LaBarre Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024 3:13 PM | Halozyme Therapeutics (Filer)
| Form PRE 14A | |
02/28/2024 5:49 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/28/2024 3:07 PM | Halozyme Therapeutics (Subject) LaBarre Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/20/2024 5:53 PM | Halozyme Therapeutics (Issuer) LaBrosse Nicole (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/20/2024 5:55 PM | Halozyme Therapeutics (Issuer) Snyder Mark Howard (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/20/2024 5:59 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/20/2024 5:49 PM | Halozyme Therapeutics (Issuer) Torley Helen (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
What is Nvidia’s New $1 Trillion SuperProject? (Ad) Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%.
Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …![](https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9285&Placement=NativeDisplay&Source=NativeDisplay) Find out details on these three critical Nvidia partners immediately. |
02/16/2024 4:39 PM | Halozyme Therapeutics (Issuer) Torley Helen (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/16/2024 4:41 PM | Halozyme Therapeutics (Issuer) LaBrosse Nicole (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/16/2024 4:47 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/12/2024 5:19 AM | Artisan Partners Limited Partnership (Filed by) Halozyme Therapeutics (Subject)
| Form SC 13G/A | |
02/01/2024 2:51 PM | Halozyme Therapeutics (Subject) Invesco Ltd. (Filed by)
| Form SC 13G/A | |
01/17/2024 3:56 PM | Halozyme Therapeutics (Subject) LaBarre Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2024 7:10 AM | Halozyme Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/16/2024 3:26 PM | Halozyme Therapeutics (Subject) LaBarre Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/13/2023 6:48 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/13/2023 3:40 PM | Halozyme Therapeutics (Subject) LaBarre Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/12/2023 3:21 PM | Halozyme Therapeutics (Subject) LaBarre Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/14/2023 3:19 PM | Halozyme Therapeutics (Subject) LaBarre Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/06/2023 3:04 PM | Halozyme Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/06/2023 3:07 PM | Halozyme Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
10/17/2023 6:28 PM | Halozyme Therapeutics (Issuer) LaBarre Michael J. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/19/2023 3:30 PM | Halozyme Therapeutics (Subject) LaBarre Michael J. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/07/2023 6:14 AM | Halozyme Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |